LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Sana Biotechnology Inc

Geschlossen

BrancheGesundheitswesen

2.82 -1.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.79

Max

2.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

-320K

-49M

EPS

-0.2

Angestellte

194

EBITDA

-1.8M

-47M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+218.97% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

163M

589M

Vorheriger Eröffnungskurs

3.87

Vorheriger Schlusskurs

2.82

Nachrichtenstimmung

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Sana Biotechnology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Juni 2025, 20:51 UTC

Ergebnisse

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. Juni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Juni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. Juni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. Juni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. Juni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:57 UTC

Akquisitionen, Fusionen, Übernahmen

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. Juni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Juni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. Juni 2025, 18:39 UTC

Market Talk
Ergebnisse

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. Juni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. Juni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. Juni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. Juni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. Juni 2025, 17:08 UTC

Ergebnisse

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. Juni 2025, 16:52 UTC

Akquisitionen, Fusionen, Übernahmen

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. Juni 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. Juni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. Juni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. Juni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. Juni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. Juni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer-Vergleich

Kursveränderung

Sana Biotechnology Inc Prognose

Kursziel

By TipRanks

218.97% Vorteil

12-Monats-Prognose

Durchschnitt 9.25 USD  218.97%

Hoch 15 USD

Tief 5 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sana Biotechnology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

1.68 / 1.87Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

154 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.